Novo Nordisk A/S (Novo Nordisk A/S) Accounts Payable : $3,746 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Accounts Payable?

Novo Nordisk A/S's Accounts Payable for the quarter that ended in Dec. 2023 was $3,746 Mil.

Novo Nordisk A/S's quarterly Accounts Payable increased from Jun. 2023 ($2,589 Mil) to Sep. 2023 ($2,877 Mil) and increased from Sep. 2023 ($2,877 Mil) to Dec. 2023 ($3,746 Mil).

Novo Nordisk A/S's annual Accounts Payable increased from Dec. 2021 ($1,348 Mil) to Dec. 2022 ($2,219 Mil) and increased from Dec. 2022 ($2,219 Mil) to Dec. 2023 ($3,746 Mil).

Novo Nordisk A/S Accounts Payable Historical Data

The historical data trend for Novo Nordisk A/S's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Accounts Payable Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

945.72

934.85

1,347.82

2,219.45

3,746.42

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable	Get a 7-Day Free Trial															2,219.45	1,445.59	2,588.51	2,877.34	3,746.42

Novo Nordisk A/S Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Novo Nordisk A/S Accounts Payable Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.